Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016
Published Sep 14, 2016
58 pages — Published Sep 14, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016, provides in depth analysis on Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted pipeline therapeutics.

The report provides comprehensive information on the Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)
- The report reviews Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strate

  
Source:
Document ID
GMDHC0525TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Overview71
Therapeutics Development83
  Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Products under Development by Stage of Development81
  Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Products under Development by Therapy Area91
  Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Products under Development by Indication101
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Products under Development by Companies132
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Products under Development by Universities/Institutes152
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Therapeutics Assessment174
  Assessment by Monotherapy/Combination Products171
  Assessment by Mechanism of Action181
  Assessment by Route of Administration191
  Assessment by Molecule Type201
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Companies Involved in Therapeutics Development217
  Amgen Inc.211
  Bristol-Myers Squibb Company221
  Chong Kun Dang Pharmaceutical Corp.231
  Japan Tobacco Inc.241
  Kowa Company, Ltd.251
  Merck &Co., Inc.261
  Pfizer Inc.271
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Drug Profiles2813
  AMG-899 Drug Profile282
  anacetrapib Drug Profile302
  BMS-795311 Drug Profile321
  CKD-519 Drug Profile331
  dalcetrapib Drug Profile344
  HL-16 Drug Profile381
  K-312 Drug Profile391
  PF-04445597 Drug Profile401
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Dormant Projects411
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Discontinued Products423
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Featured News &Press Releases4512
  Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial451
  Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics451
  Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial462
  Nov 13, 2015: Merck Provides Update on REVEAL Outcomes Study481
  Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery481
  Jun 03, 2015: Dezima Pharma s CETP Inhibitor, TA-8995, Phase 2b (TULIP) Study Results Published in The Lancet491
  Jan 12, 2015: A World First - Discovery of a personalized therapy for cardiovascular disease501
  Nov 13, 2014: Dezima Pharma Announces Complete Enrolment of CETP Inhibitor TA-8995 Study in Subjects With Isolated, Elevated Lipoprotein(a) Levels501
  Aug 29, 2014: Dezima Reports Positive Results in its Phase 2b TULIP Trial with CETP Inhibitor TA-8995 in Dyslipidemia511
  Jul 08, 2014: Dezima Pharma extends clinical development program for its CETP Inhibitor TA-8995521
  Jan 13, 2014: Dezima Pharma Completes Patient Enrolment for TULIP Phase 2B Study with CETP Inhibitor TA-8995521
  Aug 29, 2013: Dezima Pharma initiates Phase 2b TULIP study on CETP inhibitor program DEZ-001531
  Nov 05, 2012: Roche's Dalcetrapib Increases HDL Levels But Fails To Reduce Risk Of Cardiovascular Events, Study Finds541
  Aug 26, 2012: Merck Provides Update On Anacetrapib Development Program551
  May 07, 2012: Roche Provides Update On Phase III Study Of Dalcetrapib552
Appendix572
  Methodology571
  Coverage571
  Secondary Research571
  Primary Research571
  Expert Panel Validation571
  Contact Us571
  Disclaimer581

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016" Sep 14, 2016. Alacra Store. May 10, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cholesteryl-Ester-Transfer-Protein-Lipid-Transfer-Protein-I-or-CETP-Pipeline-Review-H2-2016-2088-16566>
  
APA:
Global Markets Direct - Market Research. (2016). Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016 Sep 14, 2016. New York, NY: Alacra Store. Retrieved May 10, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cholesteryl-Ester-Transfer-Protein-Lipid-Transfer-Protein-I-or-CETP-Pipeline-Review-H2-2016-2088-16566>
  
US$ 3,500.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.